文献速递高血压

超声肾去神经术与假手术在药物升级后对难治性高血压的6个月预设分析:RADIANCE-HTN TRIO随机临床试验

Effects of Renal Denervation vs Sham in Resistant Hypertension After Medication Escalation: Prespecified Analysis at 6 Months of the RADIANCE-HTN TRIO Randomized Clinical Trial.
PubMed 文献 · JAMA Cardiol · 2022-01-01

RADIANCE-HTN TRIO试验预设分析显示,难治性高血压患者接受超声肾去神经术(uRDN)或假手术后,从2个月起若家庭血压≥135/85 mmHg则启动标准化阶梯降压治疗(起始醛固酮拮抗剂)。不良事件少见且组间相似。

要点

  • 日间动态血压降幅两组相似(uRDN 138.3 vs 假手术139.0 mmHg)。

核心结论

  • 在2个月时血压仍升高的难治性高血压患者中,标准化阶梯降压治疗使uRDN与假手术组6个月血压降幅相似。
  • uRDN组所需额外降压药物更少。

研究设计与样本

  • 随机、假手术对照、患者和结局评估者盲法的国际多中心临床试验,纳入美国与欧洲患者。
  • 患者经4周单药复方三联治疗(血管紧张素受体阻滞剂、钙通道阻滞剂、噻嗪类利尿剂)后日间动态血压≥135/85 mmHg且eGFR≥40 mL/min/1.73 m²。
  • 随机分配至uRDN或假手术,2个月内药物不变;2至5个月若每月家庭血压≥135/85 mmHg则启动标准化阶梯降压治疗(起始醛固酮拮抗剂)。
  • uRDN组65/69例和假手术组64/67例有6个月日间动态血压测量,平均年龄52.4岁,男性104例(80.6%),平均eGFR 81.5 mL/min/1.73 m²。

主要发现

  • 6个月日间动态血压uRDN组138.3 mmHg vs 假手术组139.0 mmHg(自2个月额外下降-2.4 vs -7.0 mmHg)。
  • 不良事件少见且组间相似。

临床怎么用

  • 对于三联治疗下血压仍≥135/85 mmHg的难治性高血压患者,uRDN可能减少后续降压药物需求。
  • uRDN后血压管理仍可能需要标准化阶梯治疗,但所需药物种类更少。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Although early trials of endovascular renal denervation (RDN) for patients with resistant hypertension (RHTN) reported inconsistent results, ultrasound RDN (uRDN) was found to decrease blood pressure (BP) vs sham at 2 months in patients with RHTN taking stable background medications in the Study of the ReCor Medical Paradise System in Clinical Hypertension (RADIANCE-HTN TRIO) trial. OBJECTIVES: To report the prespecified analysis of the persistence of the BP effects and safety of uRDN vs sham at 6 months in conjunction with escalating antihypertensive medications. DESIGN, SETTING, AND PARTICIPANTS: This randomized, sham-controlled, clinical trial with outcome assessors and patients blinded to treatment assignment, enrolled patients from March 11, 2016, to March 13, 2020. This was an international, multicenter study conducted in the US and Europe. Participants with daytime ambulatory BP of 135/85 mm Hg or higher after 4 weeks of single-pill triple-combination treatment (angiotensin-receptor blocker, calcium channel blocker, and thiazide diuretic) with estimated glomerular filtration rate (eGFR) of 40 mL/min/1.73 m2 or greater were randomly assigned to uRDN or sham with medications unchanged through 2 months. From 2 to 5 months, if monthly home BP was 135/85 mm Hg or higher, standardized stepped-care antihypertensive treatment starting with aldosterone antagonists was initiated under blinding to treatment assignment. INTERVENTIONS: uRDN vs sham procedure in conjunction with added medications to target BP control. MAIN OUTCOMES AND MEASURES: Six-month change in medications, change in daytime ambulatory systolic BP, change in home systolic BP adjusted for baseline BP and medications, and safety. RESULTS: A total of 65 of 69 participants in the uRDN group and 64 of 67 participants in the sham group (mean [SD] age, 52.4 [8.3] years; 104 male [80.6%]) with a mean (SD) eGFR of 81.5 (22.8) mL/min/1.73 m2 had 6-month daytime ambulatory BP measurements. Fewer medications were added in the uRDN group (mean [SD], 0.7 [1.0] medications) vs sham (mean [SD], 1.1 [1.1] medications; P = .045) and fewer patients in the uRDN group received aldosterone antagonists at 6 months (26 of 65 [40.0%] vs 39 of 64 [60.9%]; P = .02). Despite less intensive standardized stepped-care antihypertensive treatment, mean (SD) daytime ambulatory BP at 6 months was 138.3 (15.1) mm Hg with uRDN vs 139.0 (14.3) mm Hg with sham (additional decreases of -2.4 [16.6] vs -7.0 [16.7] mm Hg from month 2, respectively), whereas home SBP was lowered to a greater extent with uRDN by 4.3 mm Hg (95% CI, 0.5-8.1 mm Hg; P = .03) in a mixed model adjusting for baseline and number of medications. Adverse events were infrequent and similar between groups. CONCLUSIONS AND RELEVANCE: In this study, in patients with RHTN initially randomly assigned to uRDN or a sham procedure and who had persistent elevation of BP at 2 months after the procedure, standardized stepped-care antihypertensive treatment escalation resulted in similar BP reduction in both groups at 6 months, with fewer additional medications required in the uRDN group. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02649426.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Azizi M, Mahfoud F, Weber MA, et al. Effects of Renal Denervation vs Sham in Resistant Hypertension After Medication Escalation: Prespecified Analysis at 6 Months of the RADIANCE-HTN TRIO Randomized Clinical Trial. JAMA Cardiol. 2022. PMID: 36350593. doi:10.1001/jamacardio.2022.3904

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。